Posts Tagged ‘FDA’

The Psychiatric Scientific Double Standard

Saturday, March 30th, 2019

When it comes to psychiatric scientific research, there is a double standard that favors what makes money and disavows what does not make money. When we say “double standard” we mean some rule or principle which is unfairly applied in different ways to different groups or situations, or that favors one group or situation over another. The actual principle in question here is called “evidence-based science.”

Many scientists, particularly those in the psychiatric-pharmaceutical industry, mouth that they favor “evidence-based science” when in fact they favor what can make the most money regardless of the evidence.

A recent Scientific American editorial (“The WHO Takes a Reckless Step“, April, 2019) denigrates Traditional Chinese Medicine because it is purportedly not “evidence-based.”

Yet Scientific American promotes psychiatry and psychiatric drugs, when it knows that every psychiatric drug on the market has somewhere in its fine print a statement to the effect that “we don’t know how it works,” while the FDA approves these drugs based on so-called “evidence.”

Here are some representative quotes:

  • The fine print for Rexulti (brexpiprazole, an antipsychotic) says, “the exact way REXULTI works is unknown”.
  • The fine print for Latuda (lurasidone, an antipsychotic) says, “It’s not known exactly how LATUDA works, and the precise way antipsychotics work is also unknown”.
  • The fine print for Xanax (alprazolam, a benzodiazepine anti-anxiety drug) says, “Their exact mechanism of action is unknown”.

So much for evidence-based practice! The actual evidence is, they don’t have a clue how these drugs are supposed to work — it’s all conjecture!

As we continue to examine the actual evidence, we come up against the adverse reactions, or side effects, of these drugs. This is hard evidence, not conjecture.

What is a Side Effect?

Side effects (also called “adverse reactions”) are the body’s natural response to having a chemical disrupt its normal functioning.

One could also say that there are no drug side effects, these adverse reactions are actually the drug’s real effects; some of these effects just happen to be unwanted.

The FDA takes the adverse side effect of suicide seriously by placing a Black Box Warning on certain psychiatric drugs. For example, the FDA says that “Antidepressants increase the risk of suicidal thinking and behavior (suicidality) in children and adolescents with MDD [Major Depressive Disorder] and other psychiatric disorders.”

What about those who say psychotropic drugs really did make them feel better? Psychotropic drugs may relieve the pressure that an underlying physical problem could be causing but they do not treat, correct or cure any physical disease or condition. This relief may have the person thinking he is better but the relief is not evidence that a psychiatric disorder exists. Ask an illicit drug user whether he feels better when snorting cocaine or smoking dope and he’ll believe that he is, even while the drugs are actually damaging him. Some drugs that are prescribed to treat depression can have a “damping down” effect. They suppress the physical feelings associated with “depression” but they are not alleviating the condition or targeting what is causing it.

Once the drug has worn off, the original problem remains. As a solution or cure to life’s problems, psychotropic drugs do not work.

For the first time the side effects of psychiatric drugs that have been reported to the U.S. Food and Drug Administration (FDA) by doctors, pharmacists, other health care providers and consumers have been decrypted from the FDA’s MedWatch reporting system and been made available to the public in an easy to search psychiatric drug side effects database and search engine. This database is provided as a free public service by the mental health watchdog, Citizens Commission on Human Rights International (CCHR).

Hear This — Zone Out on Zonisamide

Saturday, March 23rd, 2019

The March 15-21, 2019 issue of the St. Louis Business Journal noted a $10.5 million Army grant to the Washington University in St. Louis Medical School to study the epilepsy drug Zonisamide to see if it could prevent hearing loss from loud noises. This seemed like such an imaginative stretch that we decided to look into it in more detail.

The justification given is that Zonisamide is conjectured to protect hearing loss when given ahead of exposure to loud noises. We wondered how this came about. We also note that other epilepsy drugs are psych-related, so we wondered if there was a psych drug connection here as well.

In a rat study, researchers proposed using a substance that blocks calcium channels to see if it could prevent hearing loss against loud noises. Zonisamide also blocks calcium channels. Gee, maybe Zonisamide can prevent hearing loss.

Zonisamide is the generic name used in the United States for a seizure drug whose common brand name is Zonegran. It was first used in Japan in the early 1970’s to treat so-called psychiatric disorders, and has been used off-label by psychiatrists in the U.S. as a mood stabilizer. The FDA approved it for seizures in 2000, although it is totally unknown as to how it works to prevent seizures. The FDA notes that taking this drug may increase the risk of depression, psychosis and suicidal thoughts or actions.

Using Zonisamide during pregnancy may present a significant risk to the fetus due to the possibility of birth defects.

Zonisamide was first studied in Japan in the 1970’s during exploratory research on drugs for psychiatric disorders. The drug alters the concentration of dopamine in the brain, but is apparently dosage dependent — that is, different dosages can increase or decrease dopamine concentrations, leading to unpredictable results.

Zonisamide is metabolized in the liver by Cytochrome P450 enzymes, so its side effects can be magnified in those persons with a genetic lack of these enzymes.

Typically we see that the psychiatric research community makes a guess about re-purposing some old drug so it can be re-used for a new patient population, guesses how it might work in the rat brain, then guesses how it might work in the human brain, each time asking for more funding to make further guesses, eventually leading to the FDA approving a new use for an old drug even though they still don’t know how it “works.”

While medicine has advanced on a scientific path to major discoveries and cures, psychiatry has never evolved scientifically and is no closer to understanding or curing mental problems, thus must continually seek to find new uses for old treatments.

While medicine has nurtured an enviable record of achievements and general popular acceptance, the public still links psychiatry to snake pits, straitjackets, and “One Flew Over the Cuckoo’s Nest.” Psychiatry continues to foster that valid impression with its development of such brutal treatments as ECT, psychosurgery, the chemical straitjacket caused by antipsychotic drugs, and its long record of treatment failures including Zonisamide as a mood stabilizer.

In over 40 years, “biological psychiatry” has yet to validate a single psychiatric condition/diagnosis as an abnormality/disease, or as anything neurological, biological, chemically imbalanced or genetic.

The drugs prescribed for psychiatric conditions, such as using Zonisamide as a mood stabilizer, only exacerbate the conditions they are supposed to treat. And when these drugs are used for other non-psychiatric conditions, they continue having the same adverse reactions, such as depression and suicide when Zonisamide is used for epilepsy. It will have the same adverse reactions if it is ever used for hearing loss. And they will still not know how it “works.”

We suggest that funding only be provided for workable medical treatments that dramatically improve and cure health and mental health problems. For more information, download and read the CCHR booklet “Psychiatric Hoax – The Subversion of Medicine – Report and recommendations on psychiatry’s destructive impact on health care.

Knock Yourself Out with Spravato (Esketamine)

Monday, March 18th, 2019

A nasal spray version of the anesthetic drug ketamine was approved by the FDA on March 5, 2019 for treatment-resistant depression.

Janssen Pharmaceuticals says that the cost for a one-month course of treatment for Spravato (generic esketamine) will be between $4,720 and $6,785.

Esketamine is the S-enantiomer of ketamine, which means that it is one of the two mirror images of the chemical structure of ketamine, S (for the Latin sinister) being the left image. It enhances glutamine release in the brain. Glutamine is an amino acid used in the synthesis of proteins, among other things. In the brain, glutamine is used in the production of neurotransmitters. It is believed that glutamine plays a role in raising or lowering aggression levels.

Treatment requires that doses be taken, in conjunction with an oral antidepressant, in a doctor’s office or clinic, with patients monitored for at least two hours, and their experience entered in a registry.

Because of the risk of serious adverse outcomes and the potential for abuse and misuse of the drug, it is only available through a restricted distribution system. At least you can’t take it home with you.

The Spravato labeling contains a Boxed Warning that cautions that patients are at risk for sedation and difficulty with attention, judgment and thinking (dissociation), abuse and misuse, and suicidal thoughts and behaviors after administration of the drug.

Basically, it knocks you out so you don’t feel so depressed anymore. You don’t feel much of anything, actually, since you’ve just taken an anesthetic in the snout.

There were four phase 3 clinical trials; two of them failed to show any statistical improvement, but the drug was approved anyway because it was on the Fast Track and Breakthrough Therapy paths.

A 9/5/2018 update from Consumer Reports said, “All these drugs [Ketamine, Phenylbutazone, Chloramphenicol] are prohibited in beef, poultry, and pork consumed in the U.S. Yet government data obtained by Consumer Reports suggest that trace amounts of these and other banned or severely restricted drugs may appear in the U.S. meat supply more often than was previously known.”

Note that “depression” is not an actual medical illness; it is simply a symptom of some undiagnosed and untreated condition. A diagnosis of depression is a prime example of psychiatric fraud.

Any form of ketamine used to treat so-called depression is unethical and harmful, since it precludes the patient from finding out what is actually wrong and getting that treated. Psychiatrists pushing ketamine or esketamine are shameful drug pushers who are making a buck off people’s misfortune.

Go here for more information about alternatives to drugs.

Tranq Your Dog

Monday, January 14th, 2019

Paraphrasing a Lewis Carroll poem —

Speak roughly to your little dog.
And beat him when he seizes.
He only does it to annoy,
Because he knows it teases.

Imepitoin, sold under the brand name Pexion from Boehringer Ingelheim Vetmedica Inc. of St. Joseph, Missouri, is an anticonvulsant used in veterinary medicine to treat epilepsy in dogs. It was originally developed to treat epilepsy in humans, but clinical trials were terminated upon findings of unfavorable metabolic differences between smokers and non-smokers.

Anticonvulsants are also increasingly being used in the treatment of so-called bipolar disorder and borderline personality disorder, since many seem to act as mood stabilizers.

Pexion is similar to Valium and other benzodiazepines (anti-anxiety drugs or minor tranquilizers), acting as a low affinity partial agonist of the benzodiazepine receptor, which means that it acts in the brain similar to a benzodiazepine. It is very unusual for any dog with epilepsy to become completely seizure free even after they have begun taking this drug.

The theory is that the drug suppresses electrical activity in the brain.

On December 4, 2018, the U.S. FDA approved Pexion to treat anxiety in dogs freaked out by noises. In other words, it’s a tranquilizer for dogs.

Dog owners are cautioned to carefully monitor its use, since a side effect can be a change in the dog’s level of aggression. Well guess what, a side effect of these kinds of drugs in humans is also aggressive behavior. Some tranquilizer!

The FDA urges pet owners and veterinarians to report side effects.

It used to be only psychiatrists who prescribed tranquilizers; then family doctors became common prescribers; and now veterinarians have entered the psychiatric industry, ready to psychoanalyze your dog and prescribe a tranq.

Daily use of benzodiazepines in humans is associated with physical dependence. The withdrawal from drugs like these is more prolonged and often more difficult than withdrawal from heroin. Although dogs have not so far shown addiction to Pexion, physical dependence is a known side effect of other antiepileptic drugs in dogs.

The point we want to make is that the psychiatric industry makes a concerted effort to create new patient classes for their coercive and abusive treatments, and in this case that includes pets. We wrote about Prozac for pets way back in 2011, so this trend is continuing.

A primary care physician or family practitioner who refuses to prescribe a psychiatric drug can be accused of being unethical, or even charged and jailed for “criminal medical negligence” because they are not applying the current “standard of care.” Soon your veterinarian may find themselves criminally liable for not prescribing tranquilizers for your pet.

For more information, download and read the CCHR booklet, “Psychiatric Hoax – The Subversion of Medicine – Report and recommendations on psychiatry’s destructive impact on health care.

Rexulti Fails to Get Results

Monday, November 26th, 2018

REXULTI (generic brexpiprazole) is a prescription psychiatric drug from Otsuka Pharmaceutical Company and Lundbeck pharmaceutical company. Although it failed Phase II clinical trials for attention-deficit hyperactivity disorder (ADHD), it was approved by the U.S. Food and Drug Administration (FDA) in 2015 as an atypical antipsychotic and prescribed for the fake “disease” schizophrenia.

Then in 2018 the FDA approved it to treat symptoms of depression when antidepressants alone do not relieve symptoms.

The cost for Rexulti oral tablet 0.25 mg is around $1,166 for a supply of 30 tablets. It has similarities to Abilify, and apparently it was developed to replace Abilify when that drug’s patent expired in 2014.

Brexpiprazole affects the levels of the neurotransmitters dopamine and serotonin in the brain. It is thought to reduce dopamine output when dopamine concentrations are high and increase dopamine output when dopamine concentrations are low. It also activates serotonin receptors to increase serotonin levels in a manner thought to reduce hallucinogenic effects, which is a problem with all drugs that mess with serotonin in the brain.

The metabolism of the drug — that is, the mechanism which eventually eliminates it from the body — is mediated by Cytochrome P450 enzymes; people who are known poor metabolizers, i.e. those with a genetic lack of these enzymes, should be instructed to take half the usual dose, although this is rarely done, since the patient must first be tested for this genetic condition. It is estimated that 10% of Caucasians and 7% of African Americans are Cytochrome P450 deficient. The consequences for someone with this deficiency who takes this drug are an increased risk for the accumulation of the non-metabolized drug in the body and the resultant increase in adverse side effects such as depression, violence and suicide.

Drugs like Rexulti can raise the risk of death in the elderly, and it is not approved for the treatment of patients with dementia-related psychosis. This drug may also increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment. It is not approved for the treatment of people younger than 18 years of age.

Rexulti may cause other serious side effects, including: compulsive, uncontrollable behaviors such as gambling, shopping, binge eating and sex (the same as with Abilify); stroke in elderly people; Neuroleptic Malignant Syndrome; high fever; stiff muscles; confusion; sweating; changes in pulse, heart rate, or blood pressure; high blood sugar (hyperglycemia); weight gain; seizures; difficulty swallowing; uncontrolled body movements known as tardive dyskinesia. Tardive dyskinesia may not go away, even after one stops taking the drug, and tardive dyskinesia may also start some time after one stops taking the drug.

The real problem is that psychiatrists fraudulently diagnose life’s problems as an “illness”, and stigmatize unwanted behavior as “diseases.” Psychiatry’s stigmatizing labels, programs and treatments are harmful junk science; their diagnoses of “mental disorders” are a hoax – unscientific, fraudulent and harmful. All psychiatric treatments, not just psychiatric drugs, are dangerous. Find Out! Fight Back!

You May Be Seeing Things That Aren’t Really There

Monday, August 27th, 2018

But You Can See The Wool Being Pulled Over Your Eyes

Hallucinations and delusions are possible complications of Parkinson’s disease (PD). They are often referred to as PD psychosis. It’s estimated to occur in up to 50 percent of people with PD.

Hallucinations during PD can be frightening and debilitating. There are many factors that can contribute to hallucinations in people with PD, but the majority of cases occur as side effects of PD drugs.

Psychotic symptoms are related to high levels of a neurotransmitter known as dopamine, which is often one of the adverse reactions of psychiatric drugs.

There are many drugs that may contribute to hallucinations or delusions in people with PD, including sedatives and anti-seizure drugs.

Another danger is that a person experiencing PD psychosis may be misdiagnosed with schizophrenia and prescribed antipsychotics which may cause serious side effects and can even make hallucinations and delusions worse.

In 2016 the U.S. Food and Drug Administration (FDA) approved the antipsychotic drug pimavanserin (Nuplazid) specifically for use in PD psychosis because it does not alter levels of dopamine in the brain as much as other antipsychotics.

However, Acadia Pharmaceutical’s antipsychotic drug pimavanserin is now facing public scrutiny and fiscal uncertainty after a report from CNN in April 2018 detailed the deaths of more than 700 patients prescribed this drug since June 2016. You may be seeing advertisements for pimavanserin (Nuplazid) now in an attempt to reverse its negative publicity.

The exact mechanism of action of pimavanserin is unknown; however, it messes with the level of serotonin in the brain like other antipsychotics do. Special dosing requirements are necessary when other drugs being given along with pimavanserin have strong CYP450 interactions.

Nuplazid carries the black box warning “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.” It also has a known adverse reaction of hallucinations with 5% of those taking it, which is exactly what it is supposed to prevent. Since no one knows how it is really supposed to work, it is just a guess based on what is observed during clinical trials, with the hope that its side effects won’t be too drastic, and that enough of it can be sold before the outcry against its adverse side effects becomes loud enough to ban it.

It’s just another harmful psychiatric drug whose purpose is to make money at the expense of vulnerable people, and make more patients for life due to its damaging side effects. Click here for more information about these harmful psychiatric drugs.

Smoking is So Last Year

Thursday, February 15th, 2018

“Given the disproportionate burden of tobacco health harms in psychiatric patients, e-cigarettes are being considered as a potential tool for harm reduction.”

E-cigs are battery-powered devices that typically contain nicotine, flavorings, and other chemicals. The liquid is heated into an aerosol that the user inhales. The use of an electronic cigarette is colloquially called “vaping” as a contraction of the inhaled “vapor”. More than 2 million middle and high school students were current users of e-cigarettes in 2016. While E-cigs are not tobacco, the fact that they generally contain nicotine means that they are often considered as tobacco products. In fact, as of 2016 the FDA considers “Electronic Nicotine Delivery Systems” as regulated tobacco products, although the deadline for regulatory compliance has been extended.

Within an 18-month tobacco-treatment clinical trial with smokers with serious mental illness over a five-year period, electronic cigarette use by those recruited for the trial increased over time, from 0% in 2009 to 25% in 2013. From this data the authors concluded that serious study should be given to the use of e-cigs as a psychiatric treatment for smoking cessation and/or mental disorders.
[“E-Cigarette Use among Smokers with Serious Mental Illness“, Judith J. Prochaska & Rachel A. Grana, 11/24/2014]

Psychiatric “best practices” recommend that psychiatrists assess tobacco use at every patient visit, since tobacco addiction is covered in the DSM-V under eight separate items, and disorders related to inhalant use have 33 entries. Therefore, the psychiatric industry considers that smoking cessation therapies are their territory, which now extends into vaping.

The DSM considers that addiction is a mental illness. It is not a mental illness and cannot be fixed with psychiatric drugs. This debunked medical model of mental distress is what justifies the prescription of harmful and addictive psychiatric drugs. There is certainly such a thing as addiction and mental distress. There can be physical addiction, which requires physical detoxification; and the mental distress, resulting from a lapse of ethics and morals and not from some hokey chemical imbalance in the brain, requires its own effective treatments.

We’ve written previously about harmful psychotropic drugs being used as smoking cessation therapies. One would expect there to be new psychiatric initiatives to use these for vaping addiction, since it opens up a new class of potential [-victims-] patients for the psychiatric industry. Don’t be fooled. There are non-drug methods to stop smoking or handle other forms of addiction, including addiction to psychiatric drugs themselves. Treating substance abuse with drugs is a major policy blunder; contact your state and federal representatives and let them know you disapprove of this trend.

Psychiatric Drugs Putting Veterans at Risk of Dementia

Monday, November 20th, 2017

Almost a third of drugs cleared by the Food and Drug Administration pose safety risks that are identified only after their approval.

research study published in January, 2017 set out to determine the impact of psychotropic medication use on the association between PTSD and the risk for dementia in a nationally representative sample of US veterans aged 56 years and older.

PTSD has become blurred as a catch-all diagnosis for some 175 combinations of symptoms, becoming the label for identifying the impact of adverse events on ordinary people. This means that normal responses to catastrophic events have often been fraudulently interpreted as mental disorders. The favored “treatment” for PTSD is psychotropic drugs known to cause violence and suicide.

In their study, researchers examined information from 3,139,780 veterans aged 56 and older.

Researchers discovered that taking certain antidepressants, tranquilizers, sedatives, or antipsychotic medications significantly increased veterans’ risks for developing dementia compared to the risks for veterans who didn’t take such medications.”

The increase in the risk of dementia for veterans taking the drugs was the same whether or not they were diagnosed with PTSD.

Stated another way, patients diagnosed with PTSD using selective serotonin reuptake inhibitors, novel antidepressants, or antipsychotics were significantly more likely to be diagnosed with dementia compared to both those with and without a PTSD diagnosis but without any identified psychotropic medication use; and patients using benzodiazepines or serotonin-norepinephrine reuptake inhibitors appear to have an elevated risk for dementia diagnosis regardless of a PTSD diagnosis.

The bottom line seems to be that using psychiatric drugs increases one’s chance to develop dementia — one more reason that the first alternative to taking psychiatric drugs is just not taking them.

Click here for more information about the harm caused by psychiatric drugs.

What is Happiness?

Monday, November 6th, 2017

If you want happiness for an hour — take a nap.
If you want happiness for a day — go fishing.
If you want happiness for a year — inherit a fortune.
If you want happiness for a lifetime — help someone else.

[Chinese Proverb]

What is happiness, really? Is it “happy pills?” Mother’s little helper? Is “happiness” the opposite of “depression,” so that an anti-depressant should make one happy? Unfortunately, what anti-depressants do is actually detach one from reality; and the only happiness accrues to pharmaceutical companies who rake in $80 billion a year worldwide for psychiatric drugs.

As is usual with English words, “happiness” has more than one definition: 1) transient pleasure; 2) overcoming not unknowable obstacles toward a known goal; 3) a condition or state of well-being, contentment, pleasure; 4) joyful, cheerful, untroubled existence; 5) the reaction to having nice things happen to one.

Psychiatry, however, redefines happiness as a manic or hypomanic indication (associated with a bipolar diagnosis) which occurs in 14 separate entries in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5.)

Manic: characterized by frenetic activity or wild excitement; excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganization of behavior and elevation of mood.
Hypomanic: A mild form of mania, marked by elation and hyperactivity; a mood state characterized by persistent dis-inhibition and pervasive euphoria.

“Treatment” generally includes psychotropic mood stabilizers, unless the state is a result of drug abuse or drug side effects — in which case the “treatment” may include psychotropic sedatives. All of these psychotropic drugs are addictive, mess up the central nervous system, and can have many disastrous side effects including violence and suicide.

For more information about mood stabilizers such as Lithium, Depakote (sodium valproate), Depakene (sodium valproate), Lamictal (lamotrigine), Lamictin (lamotrigine), Lamogine (lamotrigine); download and read the booklet Mood Stabilizers — the facts about the effects.

One psychologist even overtly proposed happiness as a psychiatric disorder. [From the website of the National Center for Biotechnology Information, U.S. National Library of Medicine, a division of the National Institutes of Health]. One might think this was an April Fool’s joke, except that it was published in June.

Published in the Journal of Medical Ethics – J Med Ethics. 1992 Jun;18(2):94-8
“A proposal to classify happiness as a psychiatric disorder”
Richard P Bentall, Professor of Clinical Psychology at the University of Liverpool in the UK:

“It is proposed that happiness be classified as a psychiatric disorder and be included in future editions of the major diagnostic manuals under the new name: major affective disorder, pleasant type. In a review of the relevant literature it is shown that happiness is statistically abnormal, consists of a discrete cluster of symptoms, is associated with a range of cognitive abnormalities, and probably reflects the abnormal functioning of the central nervous system. One possible objection to this proposal remains–that happiness is not negatively valued. However, this objection is dismissed as scientifically irrelevant.”

We think we can safely say this psychologist’s attitude is a misanthropic manifestation; the DSM-5 might call it “Adult antisocial behavior”, “Antisocial personality disorder”, or maybe just “Unspecified anxiety disorder”.

It is true that a euphoric condition is often associated with certain hallucinogenic drugs. We wouldn’t actually call that “happiness”, however; and the mania associated with many psychiatric drugs is not sustainable.

What would promote happiness is an actual cure for mental distress. The psychiatric industry itself admits it has no capacity to cure. We generally take cure to mean the elimination of some unwanted condition by some effective treatment. The primary purpose of any mental health treatment must be the therapeutic care and treatment of individuals who are suffering emotional disturbance. The only effective measure of this treatment must be “patients recovering and being sent, sane, back into society as productive individuals.” This, we would call a cure.

While it is illegal for FDA-regulated products to make cure claims, there are in fact many non-drug and non-psychiatric alternatives which may prove effective in handling traumatic conditions. The trick is in finding out what is really wrong and fixing that, not just suppressing the central nervous system with drugs so that one does not feel the bad emotions.

Click here for more information about alternatives to fraudulent and abusive psychiatric treatments.

Click here for the truth about psychiatric drugs.

Click here for The Way To Happiness, the first moral code based wholly on common sense, containing twenty-one basic principles that guide one to a better quality of life.

Las Vegas in the Sights

Thursday, October 5th, 2017

Stephen Paddock massacred country music fans at an outdoor concert in Las Vegas the night of October 1, 2017 leaving 59 people dead (including Paddock) and 527 injured at last count.

He was prescribed an anti-anxiety drug in June that can lead to violent behavior, as reported by the Las Vegas Review-Journal on October 3rd.

Records from the Nevada Prescription Monitoring Program show Paddock was prescribed 50 10-milligram diazepam tablets by Henderson physician Dr. Steven Winkler on June 21. Diazepam, or Valium, is a highly addictive Benzodiazepine known to cause aggressive behavior and suicide. Chronic use or abuse of psychiatric drugs such as diazepam can also trigger psychotic experiences.

Side effects (also called “adverse reactions”) are the body’s natural response to having a chemical disrupt its normal functioning. One could also say that there are no drug side effects, these adverse reactions are actually the drug’s real effects; some of these effects just happen to be unwanted, such as the violence and suicide observed with psychiatric anti-anxiety drugs. While not everyone on psychotropic drugs commits suicide or uncontrolled acts of violence, the effects of the many other side effects, including withdrawal from these addictive drugs, can be horrendous.

For example, between 2004-2008 there were reports submitted to the FDA’s MedWatch program which included 4,895 suicides, 3,908 cases of aggression, 309 homicides and 6,945 cases of diabetes from people taking psychiatric drugs. These numbers reflect only a small percentage of the actual side effects occurring in the consumer market, as the FDA has admitted that only 1-10% of side effects are ever reported to the FDA.

Reporting of adverse reactions to psychiatric drugs by doctors, pharmacists, other health care providers and consumers once those drugs are out in the consumer market, is fundamental to drug safety monitoring. Yet these reports have been frequently ignored or dismissed as “anecdotal” by the FDA even when serious side effects number in the thousands.

For more information about how psychiatric drugs can cause violence and suicide, go here: http://cchrstl.org/sideeffects.shtml.